|
Match
|
Document |
Document Title |
|
|
7618938 |
Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly
A method for treating a cerebrovascular disease with erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) jointly by first identifying a subject in need of the treatment and then...
|
|
|
7618614 |
Hydrocephalus treatment
A method and compound for treatment of hydrocephalus is presented. Hepatocyte growth factor (HGF) is administered intraventricularly.
|
|
|
RE40988 |
Ligands of the neuropeptide receptor HFGAN72
Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose diseases relating to the under- or...
|
|
|
7611846 |
Diagnostic methods involving human growth factor huXAG-1
The present invention relates to huXAG-1, huXAG-2 and huXAG-3 proteins which are novel human growth factors. In particular, isolated nucleic acid molecules are provided encoding the huXAG-1,...
|
|
|
7608585 |
Compositions for inhibition of necrosis induced by a neurotrophin
Disclosed is a method for inhibition of necrosis induced by neurotrophin, and more specifically a method for inhibition of necrosis by administrating oxidative stress inhibitor and a method for...
|
|
|
7605127 |
Truncated hepatocyte growth factor variant protein HGF/NK2
The present invention relates to a novel truncated form of heptocyte growth factor (HGF) which specifically antagonizes the activity of HGF and to a novel truncated form of HGF that is a partial...
|
|
|
7605122 |
Human chorionic gonadotropin (hCG) formulations for facilitating weight loss and body contouring
The present invention relates to formulations of hCG for sublingual administration to mammals to facilitate weight loss and/or body contouring. Embodiments of the invention disclose administration...
|
|
|
7604993 |
Combined regulation of neural cell production
This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating...
|
|
|
7601341 |
Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
The 121-amino acid isoform of vascular endothelial growth factor (VEGF 121 ) is linked by a flexible G4S tether to a cytotoxic molecule such as toxin gelonin or granzyme B and expressed as a...
|
|
|
7598356 |
Method for purifying a protein of the cystine-knot superfamily
The present invention relates to a two-step method for isolating proteins from the cystine-knot superfamily based on dye ligand affinity chromatography and reversed-phase chromatography....
|
|
|
7598224 |
Dual chain synthetic heparin-binding growth factor analogs
The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties...
|
|
|
7597883 |
Methods for promoting growth of bone, ligament, and cartilage
Methods for promoting growth of bone, ligament, or cartilage in a mammal are disclosed. The methods comprise administering to said mammal a composition comprising a pharmacologically effective...
|
|
|
7595296 |
Mutant polypeptides of fibroblast growth factor 1
The β-trefoil protein human fibroblast growth factor-1 (FGF-1) is made up of a six-stranded anti-parallel β-barrel closed off on one end by three β-hairpins, thus exhibiting a three-fold axis of...
|
|
|
7592423 |
Globular adiponectin variants
An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does...
|
|
|
7592314 |
Use of VEGF and homologues to treat neuron disorders
The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth...
|
|
|
7592305 |
Use of ghrelin for treating malnutrition in gastrectomized individuals
The present invention relates to use of ghrelin or an analogue thereof for the preparation of a medicament for one or more of: treatment and/or prevention of loss of body weight and body fat,...
|
|
|
7589060 |
Therapeutic agent for hair-related problems and method for screening for the same
It is intended to elucidate the effect of promoting hair follicle growth and to provide the following therapeutic agents for hair-related problems (1) to (3):
(1) a hair growth promoting agent,...
|
|
|
7585943 |
Compositions and methods for fusion protein separation
The present invention relates to compositions and methods for fusion protein separation utilizing a peptide linker comprising a novel thrombin cleavage site.
|
|
|
7585835 |
GASP1: a follistatin domain containing protein
The present invention relates to the use of a protein, GASP1, comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More...
|
|
|
7585673 |
γ-heregulin
A novel member of the heregulin superfamily has been identified which is designated “γ-HRG”. This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a...
|
|
|
RE40911 |
Canine erythropoietin gene and recombinant protein
One aspect of the present invention is an isolated nucleic acid molecule encoding canine erythropoietin. The present invention also relates to an isolated canine erythropoietin protein or...
|
|
|
7582607 |
Muteins of fibroblast growth factor 21
The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity of O-glycosylation when expressed in yeast compared to wild-type human FGF-21. Both protein...
|
|
|
7576190 |
FGF-21 fusion proteins
The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a...
|
|
|
7572763 |
Follistatin domain containing proteins
The present invention relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly,...
|
|
|
7572452 |
Method for stimulating wound healing
The present invention relates to a method for stimulating wound healing, and more particularly to a method for stimulating wound healing in a subject in need thereof, comprising administering to a...
|
|
|
7569361 |
Thrombopoietin protein variants
Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate....
|
|
|
7563868 |
NRIF3, a novel co-activator for nuclear hormone receptors
Nucleic acids encoding NRIF3 are described. Polypeptides having amino acid sequences of NRIF3 proteins are also provided. A method is also provided for isolating and cloning NRIF3 cDNA. NRIF3 is...
|
|
|
7563769 |
FGF variants and methods for use thereof
The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced...
|
|
|
7563763 |
FSH and FSH variant formulations, products and methods
This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and...
|
|
|
7560101 |
Method of treatment of an infection in an animal with GM-CSF cysteine muteins in the proximal region to helix A
The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active...
|
|
|
7557195 |
Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
The present invention relates to a conjugate of a biocompatible polymer and a G-CSF bonded through a thiol group of a dysteine residue in G-CSF at a 1:1 molar ratio, and methods of preparation...
|
|
|
7557181 |
Pan-HER antagonists and methods of use
The present invention features human epidermal receptor (HER) antagonists. These antagonists are polypeptide variants of ligands of HER. The HER ligand polypeptide variants of the invention possess...
|
|
|
7556926 |
Methods for screening insulin-sensitizing agents
A compound or its salt inhibiting the activity of a protein having an amino acid sequence which is the same or substantially the same amino acid sequence as the amino acid sequence represented by...
|
|
|
7556809 |
Active antiangiogenic therapy
Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in...
|
|
|
7553941 |
Long-acting polypeptides and methods of producing same
A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a peptide-of-interest are disclosed. Pharmaceutical...
|
|
|
7553940 |
Long-acting EPO polypeptides and derivatives thereof and methods thereof
A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an EPO peptide are disclosed. Pharmaceutical...
|
|
|
7553872 |
Compounds and compositions for delivering active agents
Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
|
|
7553813 |
Methods and compositions for control of fetal growth via modulation of relaxin
The invention relates to the method for treatment, diagnosis and prevention of diseases related to fetal growth and placental insufficiency and comprises methods including inhibiting or increasing...
|
|
|
7547761 |
Low molecular weight extraction process
A process for isolating low molecular weight (“LMW”) peptides from tissue in situ comprising the steps: a) homogenizing the tissue; b) mixing the homogenized tissue with an organic solvent to...
|
|
|
7544661 |
Self-assembling peptide amphiphiles and related methods for growth factor delivery
Amphiphilic peptide compounds comprising one or more epitope sequences for binding interaction with one or more corresponding growth factors, micellar assemblies of such compounds and related...
|
|
|
7541333 |
Angiogenically effective unit dose of FGF-2 and method of use
The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO:...
|
|
|
7538197 |
Use of neuregulin-β as an indicator and/or target
The invention relates, inter alia, to the use of neuregulin-β as a target in a screening method for active compounds, in particular for exerting an influence on changes in calcium concentration...
|
|
|
7534856 |
PRO19624 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7534441 |
Immunogenic LHRH compositions and methods relating thereto
The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino...
|
|
|
7534438 |
Product and process for liquefaction of mucus or sputum
Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The...
|
|
|
7531508 |
Splice variant of the human pituitary growth hormone
This invention relates to a novel protein, termed INSP101, herein identified as a novel splice variant of human pituitary growth hormone and to the use of this protein and nucleic acid sequences...
|
|
|
7524649 |
Modified growth hormone fusion polypeptides
The invention relates to chimeric polypeptides wherein said polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and...
|
|
|
7524505 |
Compositions and methods for dual therapies of hair graying and balding in follicular delivery systems
The present invention provides comprehensive compositions for treating problems associated with hair graying and balding via the incorporation of: (i) the cell growth factor of HSCF to induce the...
|
|
|
7521528 |
Conformationally constrained parathyroid hormone (PTH) analogs with lactam bridges
The present invention relates to methods of treatment of mammalian conditions characterized by decreases in bone mass with conformationally constrained parathyroid hormone (PTH) analogs and...
|
|
|
7521233 |
Methods and devices for promoting endothelial morphogenesis
In one aspect the present invention provides methods for promoting endothelial morphogenesis. The methods of this aspect of the invention include the step of providing to one or more endothelial...
|